Pulnovo earns duo of FDA IDE nods for hypertension treatment
September 12, 2025
Pulnovo Medical announced today that it received two FDA investigational device exemption (IDE) approvals for its technology.
Pulnovo Medical announced today that it received two FDA investigational device exemption (IDE) approvals for its technology.
Naitive Technologies, a medical technology company developing AI-driven software to reimagine orthopedic care has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its flagship product, OsteoSight. OsteoSight enables opportunistic assessment of bone mineral density (BMD) using standard X-rays acquired to investigate other clinical concerns, such as pain associated with arthritis or a fall.
Advance from SMART will help to better identify disease markers and develop targeted therapies and personalized treatment for diseases such as cancer and antibiotic-resistant infection.
While vaccines can be very effective for preventing viruses, like the influenza A virus (IAV), they are often strain-specific and prone to viral escape mutations. IAV alone is responsible for around 500,000 deaths worldwide each year.
Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare condition associated with stroke, aortic dissection (tearing) and death in childhood. Currently, there is no effective treatment or cure for MSMDS.
Early and accurate diagnosis of dementia remains a major challenge. Standard approaches such as MRI and PET scans can provide valuable information about brain structure and function, but they are expensive, not always accessible, and often too expensive for repeated use.
Scientists have identified a natural extract that could help boost the effectiveness of cancer drugs. The insights gained from their study may help formulate new combination drug therapies, using precision medicine to target and cure cancer and improve patient outcomes.
A new study led by researchers from the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine) has demonstrated that artificial intelligence (AI) analysis of retinal photographs can predict an individual’s risk of cognitive decline and dementia.
Teleflex (NYSE:TFX) announced today that it enrolled the first patient in its DUBSTENT DIABETES trial.
Learn more about the biological mechanism behind the tongue movement of chameleons and salamanders, which could contribute to critical technological breakthroughs.